The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...
Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...
13d
Insmed Inc. (INSM) said it presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, ...
Considering taking supplements to treat bronchiectasis? Below is a list of common natural remedies used to treat or reduce the symptoms of bronchiectasis. Follow the links to read common uses ...
Electromed specializes in HFCWO therapy with its SmartVest System, targeting respiratory diseases. Find out my recommendation ...
Analyst Jason Zemansky of Bank of America Securities reiterated a Buy rating on Insmed (INSM – Research Report), with a price target of ...
Brensocatib, if approved, would be the first treatment for bronchiectasis and the first dipeptidyl peptidase 1 (DPP1) inhibitor, a new mechanism of action aimed at addressing a range of neutrophil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback